Fewer eye injections for wet AMD? new study tests quarterly faricimab schedule
NCT ID NCT06742307
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study tests whether faricimab injections given every 12 to 16 weeks can keep wet age-related macular degeneration (AMD) stable after an initial series of 2-4 loading doses. About 40 adults over 50 with active wet AMD will receive the quarterly schedule for one year. The goal is to see if this less frequent dosing can maintain vision and control disease activity without needing more shots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION CHOROIDAL NEOVASCULARIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Ophthalmology, United Chrisitian Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.